MoonLake Deferred Long Term Liab vs Total Stockholder Equity Analysis

MLTX Stock

USD 54.17 0.15 0.28%

MoonLake Immunotherapeuti financial indicator trend analysis is infinitely more than just investigating MoonLake Immunotherapeuti recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MoonLake Immunotherapeuti is a good investment. Please check the relationship between MoonLake Immunotherapeuti Deferred Long Term Liab and its Total Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MoonLake Immunotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Deferred Long Term Liab vs Total Stockholder Equity

Deferred Long Term Liab vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MoonLake Immunotherapeuti Deferred Long Term Liab account and Total Stockholder Equity. At this time, the significance of the direction appears to have pay attention.

The correlation between MoonLake Immunotherapeuti's Deferred Long Term Liab and Total Stockholder Equity is -0.93. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of MoonLake Immunotherapeutics, assuming nothing else is changed. The correlation between historical values of MoonLake Immunotherapeuti's Deferred Long Term Liab and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of MoonLake Immunotherapeutics are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Deferred Long Term Liab i.e., MoonLake Immunotherapeuti's Deferred Long Term Liab and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

-0.93

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from MoonLake Immunotherapeuti's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MoonLake Immunotherapeuti current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MoonLake Immunotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At this time, MoonLake Immunotherapeuti's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 2.6 B in 2024, whereas Tax Provision is likely to drop slightly above 53.6 K in 2024.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	4.6M	65.1M	54.1M	34.1M
Depreciation And Amortization	5.0K	12.4K	13.2K	12.5K

Other Operating Expenses Depreciation And Amortization

MoonLake Immunotherapeuti fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Warrants	Accounts Payable	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.05	0.57	0.28	1.0	-0.98	-0.75	0.98	-0.46	0.97	0.79	-0.14	0.36	0.33	0.97	-0.17	-0.51	-0.94	-0.7	0.98	-0.94	-0.63	0.76	0.98	0.79	-0.69
Short Long Term Debt Total	0.05		0.5	0.92	0.02	-0.21	-0.46	0.23	-0.67	0.23	-0.02	-0.71	0.3	0.94	0.23	0.98	-0.66	-0.21	-0.13	0.22	-0.21	-0.1	0.14	0.22	0.15	-0.12
Other Current Liab	0.57	0.5		0.79	0.53	-0.73	-0.97	0.72	-0.96	0.74	0.78	-0.8	0.91	0.76	0.75	0.36	-0.97	-0.59	-0.92	0.72	-0.59	-0.91	0.9	0.72	0.89	-0.91
Total Current Liabilities	0.28	0.92	0.79		0.23	-0.45	-0.75	0.47	-0.91	0.48	0.3	-0.89	0.63	0.99	0.48	0.84	-0.9	-0.43	-0.49	0.46	-0.43	-0.48	0.51	0.46	0.51	-0.49
Total Stockholder Equity	1.0	0.02	0.53	0.23		-0.97	-0.71	0.96	-0.41	0.96	0.78	-0.08	0.31	0.28	0.96	-0.2	-0.47	-0.93	-0.66	0.97	-0.93	-0.59	0.73	0.97	0.76	-0.65
Net Debt	-0.98	-0.21	-0.73	-0.45	-0.97		0.86	-1.0	0.63	-1.0	-0.85	0.31	-0.5	-0.49	-1.0	0.01	0.67	0.93	0.79	-1.0	0.93	0.73	-0.84	-1.0	-0.87	0.78
Retained Earnings	-0.75	-0.46	-0.97	-0.75	-0.71	0.86		-0.87	0.93	-0.88	-0.81	0.73	-0.84	-0.74	-0.88	-0.28	0.95	0.78	0.92	-0.86	0.78	0.9	-0.94	-0.86	-0.95	0.92
Cash	0.98	0.23	0.72	0.47	0.96	-1.0	-0.87		-0.64	1.0	0.82	-0.34	0.51	0.51	1.0	0.01	-0.69	-0.95	-0.78	1.0	-0.95	-0.72	0.84	1.0	0.87	-0.77
Non Current Assets Total	-0.46	-0.67	-0.96	-0.91	-0.41	0.63	0.93	-0.64		-0.66	-0.59	0.92	-0.89	-0.87	-0.66	-0.55	1.0	0.57	0.8	-0.63	0.57	0.8	-0.8	-0.63	-0.8	0.81
Cash And Short Term Investments	0.97	0.23	0.74	0.48	0.96	-1.0	-0.88	1.0	-0.66		0.83	-0.36	0.54	0.51	1.0	0.01	-0.7	-0.95	-0.8	1.0	-0.95	-0.75	0.86	1.0	0.88	-0.8
Common Stock Shares Outstanding	0.79	-0.02	0.78	0.3	0.78	-0.85	-0.81	0.82	-0.59	0.83		-0.26	0.65	0.3	0.83	-0.2	-0.63	-0.63	-0.92	0.82	-0.63	-0.86	0.88	0.82	0.88	-0.87
Non Current Liabilities Total	-0.14	-0.71	-0.8	-0.89	-0.08	0.31	0.73	-0.34	0.92	-0.36	-0.26		-0.84	-0.82	-0.37	-0.65	0.9	0.34	0.58	-0.33	0.34	0.63	-0.6	-0.33	-0.59	0.63
Other Current Assets	0.36	0.3	0.91	0.63	0.31	-0.5	-0.84	0.51	-0.89	0.54	0.65	-0.84		0.56	0.54	0.2	-0.88	-0.43	-0.89	0.5	-0.43	-0.93	0.87	0.5	0.85	-0.91
Total Liab	0.33	0.94	0.76	0.99	0.28	-0.49	-0.74	0.51	-0.87	0.51	0.3	-0.82	0.56		0.51	0.85	-0.87	-0.46	-0.45	0.5	-0.46	-0.43	0.47	0.5	0.48	-0.45
Total Current Assets	0.97	0.23	0.75	0.48	0.96	-1.0	-0.88	1.0	-0.66	1.0	0.83	-0.37	0.54	0.51		0.01	-0.71	-0.94	-0.81	1.0	-0.94	-0.75	0.86	1.0	0.89	-0.8
Short Term Debt	-0.17	0.98	0.36	0.84	-0.2	0.01	-0.28	0.01	-0.55	0.01	-0.2	-0.65	0.2	0.85	0.01		-0.52	0.0	0.05	0.0	0.0	0.05	-0.04	0.0	-0.04	0.05
Common Stock	-0.51	-0.66	-0.97	-0.9	-0.47	0.67	0.95	-0.69	1.0	-0.7	-0.63	0.9	-0.88	-0.87	-0.71	-0.52		0.61	0.82	-0.68	0.61	0.82	-0.83	-0.68	-0.83	0.83
Other Liab	-0.94	-0.21	-0.59	-0.43	-0.93	0.93	0.78	-0.95	0.57	-0.95	-0.63	0.34	-0.43	-0.46	-0.94	0.0	0.61		0.65	-0.95	1.0	0.62	-0.76	-0.95	-0.79	0.68
Net Tangible Assets	-0.7	-0.13	-0.92	-0.49	-0.66	0.79	0.92	-0.78	0.8	-0.8	-0.92	0.58	-0.89	-0.45	-0.81	0.05	0.82	0.65		-0.78	0.65	0.99	-0.99	-0.78	-0.98	0.99
Property Plant And Equipment Net	0.98	0.22	0.72	0.46	0.97	-1.0	-0.86	1.0	-0.63	1.0	0.82	-0.33	0.5	0.5	1.0	0.0	-0.68	-0.95	-0.78		-0.95	-0.71	0.84	1.0	0.86	-0.77
Warrants	-0.94	-0.21	-0.59	-0.43	-0.93	0.93	0.78	-0.95	0.57	-0.95	-0.63	0.34	-0.43	-0.46	-0.94	0.0	0.61	1.0	0.65	-0.95		0.62	-0.76	-0.95	-0.79	0.68
Accounts Payable	-0.63	-0.1	-0.91	-0.48	-0.59	0.73	0.9	-0.72	0.8	-0.75	-0.86	0.63	-0.93	-0.43	-0.75	0.05	0.82	0.62	0.99	-0.71	0.62		-0.98	-0.71	-0.97	1.0
Non Currrent Assets Other	0.76	0.14	0.9	0.51	0.73	-0.84	-0.94	0.84	-0.8	0.86	0.88	-0.6	0.87	0.47	0.86	-0.04	-0.83	-0.76	-0.99	0.84	-0.76	-0.98		0.84	1.0	-0.99
Net Receivables	0.98	0.22	0.72	0.46	0.97	-1.0	-0.86	1.0	-0.63	1.0	0.82	-0.33	0.5	0.5	1.0	0.0	-0.68	-0.95	-0.78	1.0	-0.95	-0.71	0.84		0.86	-0.77
Common Stock Total Equity	0.79	0.15	0.89	0.51	0.76	-0.87	-0.95	0.87	-0.8	0.88	0.88	-0.59	0.85	0.48	0.89	-0.04	-0.83	-0.79	-0.98	0.86	-0.79	-0.97	1.0	0.86		-0.99
Retained Earnings Total Equity	-0.69	-0.12	-0.91	-0.49	-0.65	0.78	0.92	-0.77	0.81	-0.8	-0.87	0.63	-0.91	-0.45	-0.8	0.05	0.83	0.68	0.99	-0.77	0.68	1.0	-0.99	-0.77	-0.99

Click cells to compare fundamentals

MoonLake Immunotherapeuti Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MoonLake Deferred Long Term Liab vs Total Stockholder Equity Analysis

Deferred Long Term Liab vs Total Stockholder Equity

Deferred Long Term Liab vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Total Stockholder Equity

MoonLake Immunotherapeuti fundamental ratios Correlations

MoonLake Immunotherapeuti Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for MoonLake Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Property Plant And Equipment Net	+ 1.0	Cash
Net Receivables	+ 1.0	Cash
Common Stock	+ 1.0	Non Current Assets Total

Net Receivables	- 1.0	Net Debt
Property Plant And Equipment Net	- 1.0	Net Debt
Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Retained Earnings Total Equity	- 0.99	Common Stock Total Equity